BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pancreas
,
Hematopoietic cell
,
Cisplatin
,
rs6983267
,
FGF21
,
Coagulation
,
Lung cancer
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Citrobacter freundii
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for Citrobacter freundii
Explore Curated Studies Results
Literature
Most Relevant Literature
Paraffin as oxygen vector modulates tyrosine phenol lyase production by Citrobacter freundii MTCC 24…
Complete sequence of the IncT-type plasmid pT-OXA-181 carrying the blaOXA-181 carbapenemase gene fro…
Isolation and identification of a bacteriocin with antibacterial and antibiofilm activity from Citro…
Pathway redesign for deoxyviolacein biosynthesis in Citrobacter freundii and characterization of thi…
Isolation and characterization of cytotoxic, aggregative Citrobacter freundii.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Inf…
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit
Vellore Typhoid Vaccine Impact Trial
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ